PMID- 32377697
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Print)
IS  - 1107-3756 (Linking)
VI  - 46
IP  - 1
DP  - 2020 Jul
TI  - Juglanin administration protects skin against UVB‑induced injury by reducing 
      Nrf2‑dependent ROS generation.
PG  - 67-82
LID - 10.3892/ijmm.2020.4589 [doi]
AB  - Extensive solar ultraviolet B (UVB) exposure of the skin results in inflammation 
      and oxidative stress, which may contribute to skin cancer. Natural products have 
      attracted attention for their role in the effective treatment of cutaneous 
      neoplasia. Juglanin is purified from the crude extract of Polygonum aviculare, 
      exhibiting anti‑oxidant, anti‑inflammatory and anti‑cancer activities. Jugalanin 
      was used in the current study to investigate whether it may ameliorate UVB 
      irradiation‑induced skin damage by reducing oxidative stress and suppressing the 
      inflammatory response in vivo and in vitro. In the present study, hairless mice 
      were exposed to UVB irradiation in the absence or presence of juglanin 
      administration for 10 weeks. The findings indicated that juglanin inhibited 
      UVB‑induced hyperplasia and decreased infiltration in the skin of mice. UVB 
      exposure‑induced oxidative stress in mice and cells was inhibited by juglanin via 
      enhancing anti‑oxidant activity. Additionally, juglanin markedly reduced 
      pro‑inflammatory cytokine release, including cyclic oxidase 2, interleukin‑1beta and 
      tumor necrosis factor‑alpha, triggered by chronic UVB irradiation. 
      Juglanin‑ameliorated skin damage was associated with its suppression of mitogen 
      activated protein kinases (MAPKs), including p38, extracellular signal 
      regulated 1/2, and c‑Jun N‑terminal kinases, as well as nuclear factor (NF)‑kappaB 
      signaling pathways, which was dependent on nuclear factor‑E2‑related factor 2 
      (Nrf2)‑modulated reactive oxygen species generation. Taken together, these data 
      indicate that juglanin protected against UVB‑triggered oxidative stress and 
      inflammatory responses by suppressing MAPK and NF‑kappaB activation via enhancing 
      Nrf2 activity.
FAU - Kong, Ying-Hui
AU  - Kong YH
AD  - Department of Dermatology, the Affiliated Huaian No. 1 People's Hospital of 
      Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China.
FAU - Xu, Su-Ping
AU  - Xu SP
AD  - Department of Dermatology, the Affiliated Huaian No. 1 People's Hospital of 
      Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200424
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (Glycosides)
RN  - 0 (Kaempferols)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 0 (juglanin)
RN  - EC 1.11.1.7 (Peroxidase)
SB  - IM
MH  - Animals
MH  - Blotting, Western
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Glycosides/*pharmacology
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaempferols/*pharmacology
MH  - Mice
MH  - NF-E2-Related Factor 2/genetics/*metabolism
MH  - Oxidative Stress/drug effects
MH  - Peroxidase/genetics/metabolism
MH  - Reactive Oxygen Species/*metabolism
MH  - Signal Transduction
MH  - Skin/*drug effects/*metabolism/radiation effects
MH  - Transforming Growth Factor beta1/metabolism
MH  - Ultraviolet Rays/*adverse effects
PMC - PMC7255487
EDAT- 2020/05/08 06:00
MHDA- 2021/03/06 06:00
PMCR- 2020/04/24
CRDT- 2020/05/08 06:00
PHST- 2017/02/24 00:00 [received]
PHST- 2019/08/04 00:00 [accepted]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/04/24 00:00 [pmc-release]
AID - ijmm-46-01-0067 [pii]
AID - 10.3892/ijmm.2020.4589 [doi]
PST - ppublish
SO  - Int J Mol Med. 2020 Jul;46(1):67-82. doi: 10.3892/ijmm.2020.4589. Epub 2020 Apr 
      24.